ProTgen Pipeline

1st Gen:

Allogeneic HSCT + ProT cell infusion for leukemia

Allogeneic HSCT for adult leukemia patients remains the best option for many

  • T cell recovery at 3 months correlates with ⬆️ overall survival, ⬇️ decreased relapse

  • ProT cell therapy takes 2 weeks post-HSCT (same as allo-CD34+ HSC donation)

  • T cell recovery expected ~3 months or less, making for practical dose selection PoC

ProTgen’s Platform Development Strategy

Clinic ready by 2027

2nd Gen:

Autologous ProT cell infusion for solid tumors

Standard of care includes radiation, ADC, oncolytic virus, CAR-Ts, etc.

  • ProT cell therapy likely to improve effectiveness of bispecific T-cell engagers (e.g., CD3-DLL3) and/or neo antigen vaccine (e.g., mRNA) treatments

  • Cells can be edited to include transient growth factors or CAR

3rd Gen:

Universal iPSC-derived ProT cells: scalable off-the-shelf immunotherapy

Hypo-immune iPSC-derived

  • Editable, cryopreservable

  • Expand in vivo after administration

  • Source of non-exhausted, expanding T cell repertoire

First Generation Platform:
Allogeneic ProT Cells for HSCT

Clinical Concepts for 2nd and 3rd Generation ProT Cells: Autologous and iPSC Off-the-Shelf

Broad T cell diversity improves survival in many solid tumor cancers (list expanding):

  • NSCLC

  • Metastatic breast cancer

  • Advanced bladder cancer

  • Advanced melanoma treated with anti-CTLA4 or anti-PD1

  • Pancreatic cancer treated with anti-CTLA4

2nd Gen: autologous ProT cells near term

3rd Gen: hypoimmune iPSC ProT cells produced at-scale at low cost